Updates are available Correction dated 2023-04-10
Click to view Correction: https://doi.org/10.1007/s13346-023-01345-4
-
Authors
El-Say, Khalid M. https://orcid.org/0000-0002-5539-3193
Al-hejaili, Omar D.
El-Sawy, Hossam S.
Alhakamy, Nabil A.
Abd-Allah, Fathy I.
Safo, Martin K.
Ahmed, Tarek A.
-
Funding
Funding for this research was provided by:
King Abdulaziz University (RG-22-166-42)
- License Information
-
More Information
Article History
Accepted: 14 February 2023
First Online: 28 February 2023
Change Date: 10 April 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s13346-023-01345-4
Declarations
:
: The in vivo investigation was conducted on healthy human volunteers at the International Centre for Bioavailability, Pharmaceutical, and Clinical Research (ICBR), Cairo, Egypt. The purpose, design, conduct, and analysis of the planned study were formally reviewed by the Institutional Review Board/Independent Ethics Committee (IRB/IEC) at ICBR. On July 18, 2019, the committee gave the study procedure its Ethical Approval Code (RESH-007). The Declaration of Helsinki and the International Conference on Harmonization (ICH) of Good Clinical Practices (GCP) were followed in conducting the study. European Medicines Agency (EMA), and Food and Drug Administration (FDA) regulations were followed during the study’s execution.
: Informed consent was obtained from all individual participants included in the study.
: Not applicable.
: The authors declare no competing interests.
